- Home
- ANVS vs MAIA Comparison
ANVS vs MAIA Comparison
Compare ANVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | MAIA |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 44.9M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANVS | MAIA |
|---|---|---|
| Price | $3.66 | $1.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 945.8K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.87 |
| 52 Week High | $5.60 | $2.74 |
Technical Indicators
Market Signals| Indicator | ANVS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 50.66 |
| Support Level | $3.58 | $1.13 |
| Resistance Level | $4.05 | $1.75 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 14.71 | 25.00 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.